Trait Name |
Trait Full Name |
Panel |
Author |
Year |
Cases* |
Controls |
TAG Set Threshold |
CSEA p (chi2) |
Age At Death | Age At Death | MTC | Pilling | 2016 | NA | 45627 | 1.00e-2 | 2.29e-2 |
Bone Mineral Density | Bone Mineral Density | MTC | Styrkarsdottir | 2008 | 4657 | 207514 | 5.00e-2 | 4.19e-2 |
Extraversion | Extraversion | MTC | De-Moor | 2012 | NA | 17375 | 1.00e-2 | 1.61e-3 |
Extraversion | Extraversion | MTC | van-den-Berg | 2016 | NA | 63030 | 1.00e-2 | 1.61e-3 |
MDD | Major Depressive Disorder | MTC | McMahon | 2010 | 6686 | 9068 | 5.00e-2 | 3.07e-2 |
Albuminuria | Microalbuminuria | MTC | Teumer | 2016 | NA | 54116 | 1.00e-3 | 7.11e-3 |
Albuminuria | Urinary Albumin to Creatinine Ratio | MTC | Teumer | 2016 | NA | 54450 | 1.00e-2 | 1.95e-2 |
Alcohol Consumption | Alcohol Consumption Men Continuous | MTC | Schumann | 2016 | NA | 27560 | 5.00e-2 | 3.71e-3 |
Alzheimers Protein Levels | Phosphorylated Tau Position 181 | MTC | Ramirez | 2014 | NA | 363 | 5.00e-2 | 4.65e-2 |
Anthropometrics Sex Stratified | Body Mass Index Women | MTC | Randall | 2013 | NA | 73137 | 5.00e-2 | 1.37e-3 |
Anthropometrics Sex Stratified | Hip Circumference Men | MTC | Randall | 2013 | NA | 34942 | 1.00e-3 | 3.71e-2 |
Aortic Valve Calcification | Mitral Annular Calcification | MTC | Thanassoulis | 2013 | NA | 3795 | 1.00e-2 | 5.98e-3 |
Autism | Autism Europeans | ETC | Psychiatric-Genomics-Consortium | 2017 | 6197 | 7377 | 5.00e-2 | 1.60e-2 |
Autism | Autism Europeans | ETC | Psychiatric-Genomics-Consortium | 2017 | 6197 | 7377 | 1.00e-2 | 5.73e-3 |
BMI Physical Activity Interaction | BMI Inactive European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 1.32e-2 |
Cognitive Functions | Memory | MTC | Davies | 2016 | NA | 112067 | 1.00e-3 | 3.23e-2 |
Ectopic Fat Traits | Pericardial Adipose Tissue Volume Men | MTC | Chu | 2017 | NA | 3640 | 1.00e-2 | 8.13e-3 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI Women | MTC | Chu | 2017 | NA | 7618 | 5.00e-2 | 3.23e-2 |
Ectopic Fat Traits | Subcutaneous Adipose Tissue Attenuation Men | MTC | Chu | 2017 | NA | 5699 | 1.00e-2 | 2.11e-2 |
Ectopic Fat Traits | Subcutaneous Adipose Tissue Volume Men | MTC | Chu | 2017 | NA | 7381 | 5.00e-2 | 3.10e-2 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14863 | 5.00e-2 | 2.79e-2 |
Facial Shape | Mod41 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.06e-2 |
Facial Shape | Mod41 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 9.75e-3 |
Facial Shape | Mod52 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.94e-3 |
Facial Shape | Mod56 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 2.66e-2 |
Glucose Stimulated Insulin Secretion | Disposition Index | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 4.80e-2 |
Glucose Stimulated Insulin Secretion | Disposition Index | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-2 | 3.59e-2 |
Glucose Stimulated Insulin Secretion | Insulin Response At 30 Minutes | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-3 | 1.58e-2 |
Insulin Secretion | Acute Insulin Response Adjusted For BMI And Insulin Sensitivity | MTC | Wood | 2017 | NA | 2087 | 5.00e-2 | 4.83e-2 |
Insulin Secretion | Acute Insulin Response Adjusted For Insulin Sensitivity | MTC | Wood | 2017 | NA | 2087 | 5.00e-2 | 4.27e-2 |
Insulin Secretion | Disposition Index | MTC | Wood | 2017 | NA | 2042 | 5.00e-2 | 2.36e-3 |
Insulin Secretion | Disposition Index Adjusted For BMI | MTC | Wood | 2017 | NA | 2042 | 5.00e-2 | 8.26e-3 |
Insulin Secretion | Peak Insulin Response | MTC | Wood | 2017 | NA | 2159 | 5.00e-2 | 4.32e-2 |
Insulin Secretion | Peak Insulin Response Adjusted For BMI And Insulin Sensitivity | MTC | Wood | 2017 | NA | 2159 | 5.00e-2 | 1.69e-2 |
Insulin Secretion | Peak Insulin Response Adjusted For BMI And Insulin Sensitivity | MTC | Wood | 2017 | NA | 2159 | 1.00e-2 | 2.95e-2 |
Insulin Secretion | Peak Insulin Response Adjusted For Insulin Sensitivity | MTC | Wood | 2017 | NA | 2159 | 5.00e-2 | 2.58e-3 |
Insulin Sensitivity Index | Model 1 | MTC | Walford | 2016 | NA | 16753 | 5.00e-2 | 3.48e-2 |
Insulin Sensitivity Index | Model 3 | MTC | Walford | 2016 | NA | 16753 | 5.00e-2 | 1.15e-2 |
Intracerebral Hemorrhage | Nonlobar ICH | MTC | Woo | 2014 | 881 | 1481 | 1.00e-3 | 4.55e-3 |
Ischaemic Stroke | All Stroke | MTC | Traylor | 2012 | 10210 | 12285 | 1.00e-3 | 4.36e-2 |
Ischaemic Stroke | Cardioembolic Stroke | MTC | Traylor | 2012 | 1715 | 12285 | 1.00e-2 | 2.83e-2 |
Ischaemic Stroke | Large Vessel Disease | MTC | Traylor | 2012 | 1877 | 12285 | 5.00e-2 | 1.71e-2 |
Lean Body Mass | Appendicular Lean Mass | MTC | Zillikens | 2017 | NA | 28330 | 1.00e-2 | 5.20e-3 |
Lymphocyte Subsets | CD19 Level | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 3.61e-2 |
TBLH BMD | Total body less head bone mineral density | MTC | Medina-Gomez | 2017 | NA | 10414 | 5.00e-2 | 2.17e-2 |
Personality Big5 | Openness To Experience | MTC | De-Moor | 2012 | NA | 17375 | 1.00e-2 | 3.98e-2 |
Pubertal Anthropometrics | Late Pubertal Height Increase Males | MTC | Cousminer | 2013 | NA | 10799 | 1.00e-2 | 9.56e-3 |
Pubertal Anthropometrics | Late Pubertal Height Increase Males | MTC | Cousminer | 2013 | NA | 10799 | 1.00e-3 | 2.29e-2 |
Pubertal Anthropometrics | Total Pubertal Height Increase Males | MTC | Cousminer | 2013 | NA | 10799 | 1.00e-2 | 2.98e-2 |
Reproductive Behavior | Age First Birth Pooled | ETC | Barban | 2016 | NA | 238064 | 1.00e-2 | 1.83e-2 |
Stroke (ischemic) | Large Artery Stroke | MTC | Traylor | 2017 | 2167 | 62004 | 5.00e-2 | 1.38e-2 |
Statin Efficacy | Delta HDL | MTC | Barber | 2010 | NA | 3928 | 5.00e-2 | 1.19e-3 |
Statin Efficacy | Delta HDL | MTC | Barber | 2010 | NA | 3928 | 1.00e-2 | 6.19e-4 |
Statin Efficacy | Delta HDL | MTC | Barber | 2010 | NA | 3928 | 1.00e-3 | 1.14e-3 |
Statin Efficacy | Delta TG | MTC | Barber | 2010 | NA | 3928 | 1.00e-2 | 1.93e-2 |
Statin Efficacy | Delta TG With Statin | MTC | Barber | 2010 | NA | 3928 | 5.00e-2 | 1.02e-2 |
Statin Efficacy | Delta TG With Statin | MTC | Barber | 2010 | NA | 3928 | 1.00e-2 | 8.06e-3 |
Type 2 Diabetes | Type 2 Diabetes | MTC | Scott | 2017 | 26676 | 132532 | 1.00e-5 | 3.23e-2 |
PAN | Pancreatic Cancer | ETC | Amundadottir | 2009 | 1771 | 1805 | 5.00e-2 | 3.66e-2 |
AUD | Alcohol Dependency | ETC | Walters | 2018 | 11569 | 34999 | 5.00e-2 | 8.26e-3 |
Ambidextrousness | Ambidextrousness | ETC | Kovel | 2019 | 5324 | 325713 | 5.00e-2 | 4.62e-2 |
Parkinsons | Parkinsons disease, age of onset | ETC | Blauwendraat | 2019 | NA | 17996 | 5.00e-2 | 2.87e-2 |
Sleep | Sleep efficiency | ETC | Jones | 2019 | NA | 84810 | 5.00e-2 | 4.68e-2 |
Sleep | Sleep efficiency | ETC | Jones | 2019 | NA | 84810 | 1.00e-2 | 1.14e-2 |
Sleep | Sleep duration variability | ETC | Jones | 2019 | NA | 84810 | 5.00e-2 | 7.91e-3 |
Sleep | Sleep duration variability | ETC | Jones | 2019 | NA | 84810 | 1.00e-2 | 4.06e-2 |
Sleep | Sleep duration variability | ETC | Jones | 2019 | NA | 84810 | 1.00e-3 | 1.05e-2 |
Neuroticism | Worry-vulnerability-special-factor-of-neuroticism | ETC | Hill | 2019 | NA | 270059 | 5.00e-2 | 1.14e-2 |
Neuroticism | Anxiety-tension-special-factor-of-neuroticism | ETC | Hill | 2019 | NA | 270059 | 5.00e-2 | 1.14e-2 |
Chronotype | Chronotype | ETC | Jones | 2019 | NA | 449734 | 1.00e-2 | 6.11e-3 |
Chronotype | Chronotype | ETC | Jones | 2019 | NA | 449734 | 1.00e-3 | 3.23e-2 |
Body fat distribution | Body fat distribution, leg fat ratio, male | ETC | Andersen | 2019 | NA | 116138 | 5.00e-2 | 9.85e-3 |
Body fat distribution | Body fat distribution-trunk-fat-ratio-male | ETC | Andersen | 2019 | NA | 116138 | 5.00e-2 | 9.63e-3 |
Brain volume | White matter hyperintensity volume | ETC | Traylor | 2019 | NA | 8429 | 5.00e-2 | 2.63e-2 |
Smoking | Smoking cessation | ETC | Liua | 2019 | NA | 547219 | 5.00e-2 | 1.98e-2 |
Smoking | Smoking cessation | ETC | Liua | 2019 | NA | 547219 | 1.00e-2 | 2.14e-2 |
Smoking | Smoking cessation | ETC | Liua | 2019 | NA | 547219 | 1.00e-3 | 4.17e-2 |
Smoking | Smoking cessation | ETC | Liua | 2019 | NA | 547219 | 1.00e-4 | 1.32e-2 |
Smoking | Smoking cessation | ETC | Liua | 2019 | NA | 547219 | 1.00e-5 | 1.12e-2 |
Smoking | Age of smoking initiation | ETC | Liua | 2019 | NA | 341427 | 5.00e-2 | 1.68e-2 |
Sleep | Sleep duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-2 | 4.64e-2 |
Physical activity | Physical activity, walking duration | ETC | Doherty | 2018 | NA | 91105 | 5.00e-2 | 4.81e-2 |
Nonischemic cardiomyopathy | Nonischemic cardiomyopathy | ETC | Aragam | 2018 | 1816 | 388326 | 5.00e-2 | 1.02e-2 |
Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 5.00e-2 | 2.91e-2 |
Medication use | Medication use (antimigraine preparations) | ETC | Wu Y | 2019 | 5,521 | 114,323 | 1.00e-5 | 2.97e-2 |
Renal cell carcinoma | Renal cell carcinoma male | ETC | Laskar RS | 2019 | 3,227 | 4,916 | 5.00e-2 | 3.66e-3 |
Nonalcoholic Liver disease | Nonalcoholic fatty liver disease | ETC | Namjou B | 2019 | 1,106 | 8,571 | 5.00e-2 | 9.08e-3 |
Stress sensitivity | Stress sensitivity (neuroticism score x major depressive disorder status interaction) | ETC | Arnau-Soler A | 2018 | 2,010 | 5,145 | 5.00e-2 | 1.65e-2 |
Longevity | Longevity (age >99th survival percentile) | ETC | Deelen J | 2019 | 3,484 | 25,483 | 5.00e-2 | 2.61e-2 |
Longevity | Longevity (age >99th survival percentile) | ETC | Deelen J | 2019 | 3,484 | 25,483 | 1.00e-2 | 8.97e-3 |
same-sex sexual behaviour | same-sex sexual behaviour | ETC | Ganna A | 2019 | NA | 408,995 | 1.00e-2 | 3.00e-2 |
Frontal lobe volume | Frontal lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 5.00e-2 | 3.26e-2 |
Height | Height variance | ETC | Wang H | 2019 | NA | 347,086 | 1.00e-2 | 7.71e-3 |
Macular degeneration | Disease progression in age-related macular degeneration (adjusted for baseline) | ETC | Yan Q | 2018 | NA | 2,721 | 5.00e-2 | 9.81e-5 |
Macular degeneration | Disease progression in age-related macular degeneration (adjusted for baseline) | ETC | Yan Q | 2018 | NA | 2,721 | 1.00e-2 | 8.95e-4 |
Cytokine network | Cytokine network levels (multivariate analysis) | ETC | Nath AP | 2019 | NA | 9,263 | 5.00e-2 | 4.27e-2 |
Cytokine network | Cytokine network levels (multivariate analysis) | ETC | Nath AP | 2019 | NA | 9,263 | 1.00e-2 | 4.59e-2 |
Cytokine network | Cytokine network levels (multivariate analysis) | ETC | Nath AP | 2019 | NA | 9,263 | 1.00e-3 | 4.78e-2 |
Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 1.00e-2 | 1.04e-2 |
Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 1.00e-3 | 3.21e-2 |
Temporale asymmetry | Planum temporale asymmetry index | ETC | Carrion-Castillo A | 2020 | NA | 18,049 | 5.00e-2 | 1.90e-2 |
Heart failure | Heart failure | ETC | Shah S | 2020 | 47,309 | 930,014 | 5.00e-2 | 2.89e-2 |
C-X-C chmokine | C-X-C motif chemokine 10 levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 3.39e-2 |
CXCL5 | CXCL5 levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 8.91e-4 |
Snoring | Snoring main | ETC | Campos AI | 2020 | 152,302 | 256,015 | 1.00e-3 | 4.09e-2 |
Snoring | Snoring main | ETC | Campos AI | 2020 | 152,302 | 256,015 | 1.00e-5 | 3.14e-2 |
Snoring | Snoring adjusted BMI | ETC | Campos AI | 2020 | 151,836 | 255,230 | 1.00e-3 | 1.99e-3 |
Snoring | Snoring adjusted BMI | ETC | Campos AI | 2020 | 151,836 | 255,230 | 1.00e-4 | 1.32e-2 |
Snoring | Snoring adjusted BMI | ETC | Campos AI | 2020 | 151,836 | 255,230 | 1.00e-5 | 3.12e-2 |
Snoring | Snoring Female | ETC | Campos AI | 2020 | 61,792 | 156,554 | 5.00e-2 | 9.15e-3 |
Snoring | Snoring Female | ETC | Campos AI | 2020 | 61,792 | 156,554 | 1.00e-2 | 2.89e-2 |
Snoring | Snoring Female | ETC | Campos AI | 2020 | 61,792 | 156,554 | 1.00e-4 | 4.91e-2 |
Retinal detachment | Retinal detachment or retinal break | ETC | Boutin TS | 2020 | 6148 | 59546 | 5.00e-2 | 3.93e-3 |
* If the number of cases is 0/NA, it means the phenotype is a continuous data type and the number of controls is the total number of samples.